Journal Papers, Abstracts, and Commentaries
|
| |
Pharmacokinetics of Efavirenz in 2-3 years old children: a high
dose of 25 mg/kg per day.
Pressiat C, Amorissani-Folquet M, Yonaba C,
Antimicrob Agents Chemother. 2017 May 8. p
Abstract
FULL-TEXT ARTICLE
Population Pharmacokinetics Analysis to Inform Efavirenz Dosing Recommendations
in Pediatric HIV Patients Aged 3 Months to 3 Years.
Luo M, Chapel S, Sevinsky H,
et al
Antimicrob Agents Chemother.
2016 Apr 11.
Paper
The impact of genetic polymorphisms on the pharmacokinetics of efavirenz in
African children.
Bienczak A, Cook A, Wiesner L, Olagunju A,
et al
Br J Clin Pharmacol. 2016 Mar
16.
Abstract
A Population Pharmacokinetic/Pharmacodynamic Model Predicts
Favorable HDL Cholesterol Changes Over the First 5 Years in Children Treated
with Current Efavirenz-Based Regimens.
Homkham N, Cressey TR, Ingsrisawang L, et al
J Clin Pharmacol. 2016 Jan 8.
Abstract
The Effect of Malnutrition on the Pharmacokinetics and Virologic
Outcomes of Lopinavir, Efavirenz and Nevirapine in Food Insecure HIV-infected
Children in Tororo, Uganda.
Bartelink IH, Savic RM,
Dorsey G, et al
Pediatr Infect Dis J. 2015
Mar;34(3):e63-e70.
Abstract
Pharmacometric Characterization of Efavirenz Developmental
Pharmacokinetics and Pharmacogenetics in Human Immunodeficiency
Virus Infected Children.
Salem AH, Fletcher CV, Brundage
RC.
Antimicrob Agents Chemother.
2013 Oct 21
Abstract
Pediatric under-dosing of efavirenz: a pharmacokinetic study
in Uganda.
Fillekes Q, Natukunda E, Balungi J,
et
al
J Acquir Immune Defic Syndr.
2011 Sep 15
Abstract
A pharmacokinetic and pharmacogenetic study of efavirenz in children: dosing
guidelines can result in
subtherapeutic concentrations.
ter Heine R, Scherpbier HJ, Crommentuyn KM, et al
Antivir Ther. 2008;13(6):779-8
Abstract |
Pharmacokinetics and Pharmacodynamics of Efavirenz and Nelfinavir in
HIV-infected Children
Participating in an Area-under-the-curve Controlled Trial.
Fletcher CV, Brundage RC, Fenton T, et al
Clin Pharmacol Ther. 2007
Jul 4;
Abstract |
Conference Reports, Abstracts, and Posters
Journal Papers, Abstracts, Letters, and Commentaries
| |
Plasma efavirenz exposure, sex, and age predict virological response in
HIV-infected African children.
Bienczak A, Denti P, Cook A,
et al
J Acquir Immune Defic Syndr.
2016 Apr 21.
Abstract
The Effect of Malnutrition on the Pharmacokinetics and
Virologic Outcomes of Lopinavir, Efavirenz and Nevirapine in Food Insecure
HIV-infected Children in Tororo, Uganda.
Bartelink IH, Savic RM, Dorsey G,
et al
Pediatr Infect Dis J. 2015
Mar;34(3):e63-e70.
Abstract
Patterns of plasma human immunodeficiency virus type 1 RNA response to
highly active antiretroviral therapy in infected children.
Spector SA, Yong FH, Cabral S et al.
Journal of Infectious Disease
2000; 182(6): 1769-1773.
Abstract |
Journal Papers, Abstracts, Letters, and Commentaries
Journal Papers, Abstracts, Letters, and Commentaries
| |
Efavirenz is associated with higher bone mass in South African children with
HIV.
Arpadi SM, Shiau S, Strehlau R,
et al
AIDS. 2016 Jul 16.
Abstract
FULL-TEXT
PDF ARTICLE
Efavirenz-induced gynecomastia in a prepubertal girl with human immunodeficiency
virus infection: a case report.
van Ramshorst MS, Kekana M, Struthers HE, et al
BMC Pediatr. 2013 Aug
13;13(1):120
Paper
FULL-TEXT
ARTICLE
Efavirenz poisoning in a 12 year old HIV negative African boy
Nazziwa R, Sekadde M, Kanyike F, et al
Pan Afr Med J.
2012;12:86.
Paper
Absence Seizures Associated With Efavirenz Initiation.
Strehlau R, Martens L, Coovadia A,
et
al
Pediatr Infect Dis J.
2011 May 31.
Abstract
Psychosis in a 12-year-old HIV-positive girl with an
increased serum concentration of efavirenz.
Lowenhaupt EA, Matson K, Qureishi B,et al
Clin Infect Dis. 2007 Nov 15;45(10):e128-30.
Abstract
|
Journal Papers, Abstracts, Letters, and Commentaries
|
| |
Virologic Response to First-line Efavirenz- or Nevirapine-based
Antiretroviral Therapy in HIV-infected African Children.
Kekitiinwa
A, Szubert AJ, Spyer M, et al
Pediatr
Infect Dis J.
2017
Jun;36(6):588-59
Abstract
Efavirenz-Based Antiretroviral Therapy Among Nevirapine-Exposed HIV-Infected
Children in South Africa: A Randomized Clinical Trial.
Coovadia A, Abrams EJ, Strehlau R, et aj
JAMA.
2015 Nov 3;314(17):1808-17.
Abstract
Efavirenz Capsule Sprinkle and Liquid Formulations with Didanosine and
Emtricitabine in HIV-1-Infected Infants and Children 3 Months to 6 Years of
Age: Study AI266-922.
Pavia-Ruz N, Rossouw M, Sáez-Llorens X, et al
Pediatr Infect Dis J.
2015 Sep 15.
Abstract
Association between efavirenz-based compared with
nevirapine-based antiretroviral regimens and virological failure in
HIV-infected children.
Lowenthal ED, Ellenberg JH,
Machine E, et al
JAMA.
2013 May 1;309(17):1803-9.
Abstract
Efficacy and tolerability of nevirapine- versus efavirenz-containing
regimens in HIV-infected Thai children.
Lapphra K, Vanprapar N, Chearskul S, et al
Int J Infect Dis. 2008 Jun 21.
Abstract
|
FULL-TEXT ARTICLE
Impact of Protease Inhibitor Substitution With Efavirenz in HIV-Infected
Children:
Results of
the First
Pediatric Switch Study.
McComsey G, Bhumbra N, Ma JF, et al
Pediatrics 2003 Mar;111(3):E275-E281
Paper
Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-
transcriptase
inhibitors in
children
infected with human immunodeficiency virus type 1.
Pediatric AIDS Clinical Trials Group 382 Team. Starr SE, Fletcher CV, et al.
New England Journal of Medicine 1999; 341(25): 1874-881.
Abstract
|
|
|
|
General
Reports
Main
New/Newsworthy
Home Page
Documents identified with this icon are in Portable Document Format (PDF)
and require the